The Problem
Capital allocators are flying blind in the age of AI.
AI tools are proliferating rapidly, but capital allocators struggle to systematically deploy them across portfolio companies. The result: fragmented tools, descriptive-only monitoring, and a complete disconnect between strategy and execution.
Three Core Challenges
Why the current stack
is broken.
AI adoption across portfolio companies is chaotic
There are thousands of AI tools available, but portfolio companies do not know which tools to adopt, where to apply them, or how to measure their impact. Capital allocators lack a systematic way to diagnose operational gaps, recommend solutions, and manage AI implementation across their entire portfolio.
Portfolio monitoring is descriptive, not actionable
Existing platforms like Allvue, iLEVEL, and Carta track financial performance — but they don't tell you what to do about it. They show you the numbers. They don't provide prescriptive guidance on how to actually improve portfolio company operations, deploy AI, or execute value-creation initiatives.
Deal sourcing and portfolio strategy are disconnected
Capital allocators use separate tools for sourcing new investments, managing portfolio companies, and executing roll-ups or value-creation strategies. There is no unified platform that links investment strategy with operational execution. Every handoff between tools means lost context, duplicated work, and slower decisions.
Market Landscape
Everyone has a piece.
No one has it all.
Existing tools solve one part of the problem. HCG moves from descriptive analytics to prescriptive operational management — across every dimension.
HCG's core differentiation
Moving from descriptive analytics to prescriptive operational management — across portfolio monitoring, AI deployment, deal sourcing, and strategy execution.